data discovery

Shivom Announces Major Update to it’s Platform, Teamwork, Overhauled UX and Data Discovery Tool for Pharma.

data discovery

Shivom’s new release seeks to provide researchers and pharmaceutical companies with a major overhaul on how drug-discovery and development are conducted. The platform has been engineered to handle the complexities of gaining access through multi-layered consent and interrogating multi-omics data in the age of remote working during the coronavirus pandemic.

LONDON, UK – September 14, 2020 – Shivom Ventures Limited (“Shivom”), a leader in biotech and data-sharing solutions, today announced a major update to its platform, an end-to-end bioinformatics suite that accelerates drug discovery and development by delivering enriched insights through AI/ML technology. Building upon its earlier releases, Shivom’s v3.0 adds new features such as teamwork, dark mode, dynamic interrogation, revolutionary new interface and more. The most celebrated feature of v3.0 is the new Discover tool, allowing researchers to explore massive sets of genomic, phenotypic, multi-omic and other structured data generated by biobanks, academic institutions and consortiums from across the globe. 

Researchers are increasingly searching within large repositories generated by academic institutions, biobanks, consortium partners and even now becoming more common, technology companies for genomic and clinical data. However, access to restricted data is making it difficult for researchers to launch new clinical research because the organisations who are storing the dating are relying on legacy technologies to officiate access between data custodians and the clientele. With most databases and biobanks, the bona fide user must apply for access with a corresponding data access control body, provide an institution ID, and a long publication record. Usually, they will need their organization’s signing official to participate in the registration process, they are asked to submit a lengthy proposal detailing the data they want to use and may need to go through an Institutional Review Board. On average, a straightforward application and approval process takes 2–3 months; sometimes it has taken up to half a year. These legacy procedures can heavily impact the time it takes to initiate clinical research and even hinder a project from ever starting. 

Dr Axel Schumacher, Shivom Co-Founder & Chief Research Officer, said, “Data sharing technologies are still extremely underutilized and most data custodians are reluctant to share their data, demonstrating that the global healthcare community needs an elemental paradigm shift in how data is shared and utilized. We developed the technology to make quick, easy, and fine-grained data sharing and data analytics a reality. The Shivom platform enables researchers to build data cohorts, making large, or expensive-to-collect, datasets available to all. Data can be reused, reanalyzed, repurposed, and mined for further insight, saving organisations valuable time and resources, thereby shortening the time to discovery. The Shivom platform makes data easily findable & searchable, and ultimately actionable, as data can be analyzed on the bioinformatics marketplace, breaking down data silos, putting data in a larger, global context. But we did not stop there and improved accessibility by avoiding complicated access procedures, promoting maximum use of research data. With better reusability, data is not stored and forgotten, but reusable in many research projects.”

Facilitating data exploration and sharing is embedded within the core of Shivom’s new release as it’s aim is to empower next-generation scientists with next-generation tools in order to solve the most complex genetic diseases and viruses.

Shivom v3.0 Key Features & Pipelines

One of the key changes on the platform as part of the revamp includes the addition of dark theme UI. With just a click of a button, the researcher can change platform surface variant from standard light background to a black/dark grey which reduces luminance. This latest change is to make research safer by reducing eye strain, which is often the case with sitting carrying large computational analysis – allowing analysis to be carried for prolonged periods of time whilst minimising the risk of concentration lapse.

Another key feature includes the launch of the long-awaited ‘teamwork’ functionality. As the scientific research community across pharmaceutical, academia and industry increase in collaboration for scientific research breakthroughs, there has been an increase in the ability to allow research to be conducted across different organisations. This new feature allows account holders to add new users/members either from consortia or partners to curate discovery datasets, initiate & monitor analyses and view result output real-time. This allows researchers to focus on science and research instead of issues with regards to sharing data, integrating platforms (cloud storage and servers) and exchanging results.

The ‘projects’ feature has been updated for v3.0 for better usability. Previously, single users had the ability to monitor analysis and refer back to an old analysis run previously, which included both parameters and result output. The update partitions analysis into ‘in progress’, ‘completed’ and ‘failed’. This allows the user to multitask and monitor different ongoing analysis with ease without losing track, but also identify failed pipelines quickly in order to fix and rerun. These changes will allow for better analysis experiences for the researcher – which can become confusing and unwieldy especially when there are dozens of analyses being run simultaneously. Furthermore, for users that are part of the ‘teamwork’ group – will have the ability to see team members icons that are running other pipelines within the group.

Finally, there has been an additional analytical pipeline to the platform. A gene set analytical tool for GWAS summary statistics and raw genotype data has been added to the suite of GWAS pipelines including Meta-analysis, PRS and Genetic Correlations. Gene set enrichment analysis is used to identify gene set groups that are enriched in the GWAS results output in order to see whether there are any associations.

Ibrahim Farah, VP of Product said. ‘Today’s launch of v3.0 marks a huge milestone at Shivom and is one of our most thorough and comprehensive updates thus far. We have made several enhancements and additions across various parts of the platform, including user interaction and experience with dark mode theme, the ability to conduct research as a team or as part of a collaboration and finally new tools to interrogate genetic datasets for biological discoveries. We aim to ensure that all our customers have the best research experience when conducting large scale analysis by taking the technical burdens required to execute such complexities whilst bringing all the tools they need to quickly run analysis, interpret and share them.’

ABOUT SHIVOM

Shivom provides 1-click access to genomic data and insights. The end-to-end cloud operating system enables computation and analysis to Omics data, accelerating drug discovery and delivering novel insights to personalised medicine. Users are able to gain easy access to genomic data and the ability to run various bioinformatics & AI tools in one environment.

Headquartered in London, UK, Shivom’s mission is to build the world’s largest genetic marketplace. Shivom’s ecosystem of partners and customers spans 10 countries including two active European pilot projects with H2020.

Shivom’s Press Contact: nate@shivom.io

Shivom Social Channels:
Official Homepage: shivom.io
Twitter: @projectshivom
Youtube: Shivom’s Channel
Facebook: @projectshivom
Instagram: @projectshivom
LinkedIn: @projectshivom

Recent Updates

View All

COVID-19

Shivom Launches v2.0; Delivering a Library of Multi-Omics COVID-19 Pipelines

COVID-19

Shivom Ventures Limited releases v2.0 which provides researchers with various new features including a library of multi-omics COVID-19 pipelines.

London, United Kingdom – April 16, 2019 – Shivom, a biotechnology data discovery and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has released v2.0. Users can now gain access to bulk data onboarding, 7 new pipelines, PayPal integration and more.

Within this release, the product team has added a library of multi-omics Covid-19 pipelines which run off of Shivom’s very own cloud solution. The rapid emergence of COVID-19 across the world has led to massive mortality and morbidity. The genome sequencing of the coronavirus (SARS-CoV-2) can provide clues regarding how the virus has evolved and variants within the genome. “As part of the current pandemic crisis, Shivom has played its part in combating the deadly disease by delivering a curated library of multi-omics analytical pipelines to COVID-19 researchers across the globe. These pipelines allow the researcher to interrogate both viral genome and human genome separately from raw sequencing data, but also combine output for more potent analysis” Said Ibrahim Farah, VP of Product.

The company has curated a set of pipelines, scientists will be able to quickly characterise the novel coronavirus by:

Identifying whether SARS-CoV-2 present in the sample;
Distinguish variant-level differences between samples;
Quantify amount of SARS-CoV present in each sample;
Detect whether susceptibility, symptomatic/asymptomatic status and disease progression is due to human genome variation

Answers to these points are crucial to aid our understanding of disease biology of SARS-CoV-2 which will lead to development of better predictive, preventative and therapeutic measures. Shivom’s intuitive interface allows for users with no experience of programming/bioinformatics analysis to upload fastq files and toggle the desired parameter options, before running the pipelines – all on the same page.

Advantages
Ease of running pipelines through simple and intuitive user interface.

Safe storage of suspected COVID-19 patients genomic information, for later reanalysis.

Built-in quality control and data manipulation for desired analysis.

Automated summary statistics .pdf reports to share with colleagues.

Additional
Traceable and secure via blockchain technology to share COVID-19 genetic data with the rest of the scientific community.

Use existing population-level genomics pipelines, to consolidate understanding of SARS-CoV-2 in relation to other complex genetic disorders.

The release will be made live to the public at 2:00 pm GMT on 16th April.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom provides 1-click access to genomic data and insights. The end-to-end cloud operating system enables computation and analysis to Omics data, accelerating drug discovery and delivering novel insights to personalised medicine. Users are able to gain easy access to genomic data and the ability to run various bioinformatics & AI tools in one environment.

Headquartered in London, UK, Shivom’s mission is to build the world’s largest genetic marketplace. Shivom’s ecosystem of partners and customers spans 10 countries including two active European pilot projects with H2020.

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recent Updates

View All

Clinical SaaS

Shivom Releases MVP; Offering Clinical SaaS-based Automated Data Analytics

Clinical SaaS

Shivom Ventures Limited releases its MVP which provides researchers with a Clinical SaaS-based platform to search for datasets and run genomic pipelines in three clicks of the mouse. 

London, United Kingdom – July 29, 2019 – Shivom, a biotechnology data discovery and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has released it’s long-awaited MVP. This release seeks to target data owners who are not only looking to securely store their DNA and other biodata but enable them to monetise their data within the research community. Through a combination of explicit consent mechanisms, blockchain and smart contract technology, data owners are provided traceability and complete control over their data.

The release will be made live to the public at 2:00 pm GMT on 29th July. This is a major milestone for Shivom, the company will now offer researchers the ability to search for datasets and run genomic pipelines in three-clicks of the mouse under their new clinical SaaS-based solutions.

“In my 20 years of experience working in the field and within biobanks led to the automation of analysis for the researchers on our platform. Using Shivom’s Clinical SaaS platform can help organisations not only reduce the cost of R&D but make research easy and accessible. Were stripping away the pre-requisites other bioinformatics platforms require the researcher to possess in order to run pipelines and tools such as GWAS or SAM Tools. With access to patient biosamples and open data, time is finally freed for the researchers who currently have to scour and prep data for analysis,” said Dr Darrol Baker, Head of Bioinformatics.

Shivom’s clinical SaaS solution will seek to solve pharma’s most hard-hitting challenges, lack of innovation in bioinformatics, increasing R&D costs and siloed data. These challenges have been solved through a unique approach by utilising the best in breed technologies at our disposal. “Utilising new innovative smart contract solutions are at the heart of the Shivom Platform to enable user consent and monetisation. Cloud-native bioinformatics analysis solutions to ensure data is always with Shivom and processing is lightning fast. Smart coding techniques for smarter smart contracts enabling storage of large amounts of data at a fraction of the gas cost. Innovative integration with Ethereum so that the user does not have to pay GAS cost to use smart contracts. Never before seen use cases for data owners to use their data as well as discover and use data on our platform. A platform for modern genomics,” said Meer Ali, Director of Technology.

Alongside updated permissions and an end-to-end solution for researchers, the MVP contains major updates to the consumer shop; offering additional 6 products, new UI and provides consumers with the choice of purchasing via OMX tokens or cash. One of the products Shivom will be offering for purchase is a DNA test which analyzes the 11 genes that are responsible for your skin’s hydration, elasticity, photoaging, and skin antioxidant protection, created by using the knowledge of modern genetics in skincare. By taking the DNA test you will receive a personalised report, which will provide you with general skincare recommendations which are important for your specific genotype. Another product that will be introduced is Strain Genie’s Cannabis DNA kit, which provides consumers with personalized insights and important warnings about how your body may or may not respond to specific cannabinoids, terpenes and strains of Cannabis.

“I’m incredibly proud of the team and their hard work and commitment to deliver on this critical milestone. With our MVP, enterprises and researchers have the ability to search and discover diverse datasets globally, enter into smart contracts with data owners and utilize our integrated, streamlined bioinformatics analysis and reporting features, while also benefiting from our blockchain-enabled audit and patient consent functionalities for compliance purposes. These innovative solutions represent a new paradigm for robust multi-omics analysis, which we anticipate will result in significant clinical efficiencies and ultimately the accelerated delivery of personalized care and therapies.” said Henry Ines, CEO of Shivom.

Following the MVP release, Shivom will focus its efforts on not only improving the customer experience but adding pipelines, support for other bioinformatic providers, enhanced reporting features and additional security layers to the Clinical Saas-based solution.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data discovery and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recent Updates

View All

Cleveland Clinic-Family-Care-Path-Shivom

Shivom Partners with Family Care Path a Spin-Off Company from Cleveland Clinic

Cleveland Clinic-Family-Care-Path-Shivom

Family Care Path’s clinically-validated MyLegacy and CarePathConnect application will provide new ways for Shivom’s customers to take action on their genetic risk for certain hereditary conditions.

London, United Kingdom – April 2, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, and Family Care Path (FCPI), a spin-off company from Cleveland Clinic adapting and marketing web-based clinical decision support applications, are collaborating to integrate FCPI’s MyLegacy application within Shivom’s marketplace. Through collaboration, Shivom’s customers can gain access to a personalised health risk profile and genomic counselling sessions which provide end-users with coaching to take proactive steps against hereditary conditions found within their genetic data.

FCPI has established an international telegenetic counselling network, branded CarePathConnect, which provides patients with the ability to privately and securely discuss their genetic health risk conditions with genetic counsellors and learn about the benefits and limitations of genetic testing via a HIPAA-compliant web-based video platform. The company exclusively licensed the family history collection and disease risk assessment tool from Cleveland Clinic, branded MyLegacy, which uses proprietary algorithms based on practice guidelines developed by the Cleveland Clinic Genomic Medicine Institute.

“Access to your genetic information is really just the beginning — using that information in combination with genetic counselling allows the necessary preventative measures to prevent serious health complications,” said Henry Ines, CEO of Shivom. “Our collaboration with Family Care Path enables Shivom’s customers to access their genetic information using a clinically validated programme to help them make lifestyle changes which seek to prevent or suppress hereditary conditions.”

The pilot for this collaboration will enable Shivom customers to access the FCP MyLegacy application and schedule a virtual genomic counselling session. Both clinical and non-clinical counselling sessions will be explored and processes will be established to ensure that customers are able to utilise both data collected from the FCP risk assessment tool as well as any genomic or other ‘omics’ reporting facilitated by Shivom subject to patient consent and permissions. Shivom also plans to arrange for its OMX token to be utilised as a means of payment and incentives for accessing counselling sessions and related services. The partnership marks a critical step in the roadmap for Shivom as it onboards key partners and services on its platform/marketplace to further demonstrate utility for its token.

“We are excited to collaborate with Shivom on this innovative effort. Working with Shivom will help their customers have a deeper understanding of their genetic information through testing, counselling and the ties to family health history” says David McKee, President and CEO of Family Care Path.

For more information about Shivom’s direct-to-consumer solutions please click here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Shivom Social Channels:
● Official Homepage: shivom.io
● Twitter (English): @projectshivom
● Youtube: Shivom’s Channel
● Telegram: Shivom Announcements
● Facebook: @projectshivom
● Instagram: @projectshivom
● Medium: Shivom Official
● LinkedIn: @projectshivom

About Family Care Path
Family Care Path develops, adapts and markets web-based clinical software applications designed to improve patient outcomes, increase physician and clinical process efficiency, and interface with a variety of electronic health records.

Many exciting concepts for healthcare applications remain isolated within the development environment. Our company’s mission is to identify these opportunities and develop software solutions utilising industry standard protocols, to enable widespread adoption.

We utilise the latest technology to develop secure and scalable applications to improve the quality of healthcare and reduce cost. Leveraging industry standard technologies such as Microsoft Cloud and both the SMART® and HL7® FHIR® open standards, Family Care Path creates applications which can seamlessly communicate with all electronic health record systems.

For more information about Family Care Path please visit:
www.familycarepath.com

Recent Updates

View All

Shivom-Alpha-2.0-Release

Shivom Releases Alpha 2.0 to Genomic Researchers & Data Owners

Shivom-Alpha-2.0-Release

Shivom – a data discovery and analysis solutions platform – on Tuesday unveiled its second release – Alpha 2.0. Leveraging the latest advancements in blockchain and machine-learning technology, Shivom is optimising how DNA is shared, secured and analysed in order to bring exponential value to the genomics industry.

In November 2018, Shivom launched its first release amid great enthusiasm and fervour. Since then, the product and development teams have been working on fixing bugs and integrating new features that have come from their recent partnership with Lifebit. In its first release, it streamlined its UI/UX and USPs based on the need to innovate in the area of secure storage. It also had multiple new-age features such as simplified sign-up DNA upload & encryption, etc.

Continuing its efforts in the area of innovation, Shivom continued developing on the previous release and has now launched its second release – Alpha 2.O. The latest advancements in the platform include avatars, issuing of notifications, bug-fixing throughout the platform, enterprise search functionality, an upgraded UI, and finally our blockchain transaction and verification for DNA file-uploading.

With the above-mentioned substantial updates, the platform can now verify via blockchain when a file is uploaded, secured and encrypted via Shivom. The next release titled ‘MVP’ will set to deliver DNA sequencing kits, an integrated wallet, marketplace and secure-sharing features. With a successful and well-tested second release, Shivom is steering itself into capturing a mega segment in this market.

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies and pharmaceutical companies with the ability to securely share, store and analyse DNA data quickly, efficiently and at any scale. such as blockchain and machine-learning algorithms, we are able to democratise genomics. Doing so, we empower data-owners, researchers To learn more about the project, visit the Shivom website.

Shivom Social Channels:
● Official Homepage: shivom.io
● Twitter (English): @projectshivom
● Youtube: Shivom’s Channel
● Telegram: Shivom Community
● Facebook: @projectshivom
● Instagram: @projectshivom
● Medium: Shivom Official
● LinkedIn: @projectshivom

Recent Updates

View All

Shivom Partners With Lifebit

Blockchain genomics pioneer and AI data analysis firm will provide pharmaceutical organizations and life science users with comprehensive reporting through a library of pipelines

London, United Kingdom – 11 December 2018 – Shivom, the blockchain genomics platform that is powering personalized healthcare, has partnered with Lifebit, the AI-powered DNA-analysis firm, to give users unprecedented reporting capabilities for DNA data analysis.

The partnership will mean that immediate Genome Wide Association Study (GWAS) analysis is possible, with no specialist knowledge or in-house data scientist required. It also means that users can access a library of pipelines (ready built software that are used for analysis) and an AI-powered toolkit for analysing the data in a way that is far more scalable than other solutions.

Another aspect that makes the Shivom platform superior to other genomics platforms is that it will give pharmaceutical organizations and life sciencee users the ability to access real-time analysis whenever they need it with no waiting time, no application process for accessing the data and deadlines or cut off dates that restrict their access.

“Through this partnership with Lifebit, we are providing enterprise users with the tools they need to find the right patients for their clinical trials more easily and more accurately than is possible through other solutions. Not only that, it brings AI into GWAS analysis in a way that hasn’t been seen before,” said Dr Axel Schumacher, Co-Founder and Chief Scientific of Shivom.

The use of genomics platforms to improve rare disease treatment has increased in recent months, with 23andMe partnering with GlaxoSmithKline to develop drugs for Parkinson’s. However, the Shivom Lifebit partnership demonstrates a major leap forward in this area because it adds AI and Machine Learning capabilities to the identification of potential patients.

To do this, users will be able to access a library of pipelines within the Shivom platform. These include preset Shivom pipelines, those created through open source software and any that an enterprise chooses to develop using Github and DOCKER services.

“Our partnership with Shivom will allow us to combine unique datasets with a level of analysis automation and insight generation that has never been seen before on a genomics platform,” said Dr. Maria Chatzou, co-founder and CEO of Lifebit. “In this way, scientists and doctors will be able to get all the benefits of this rich database without the need to rely on a data scientist for help. On the other hand, still ensuring that the individuals that have provided data to Shivom are given a level of security and control only a state-of-art blockchain technology can offer.”

The partnership with Lifebit comes with the Shivom platform having already been released in alpha. The full launch of the platform is expected in Q1 2019.

-ends-

Media Contact:
Frances Wells
Cryptoland PR
E: frances@cryptolandpr.com
US: 866–586–5603
UK: +44 020 3908 5686

About Shivom:
Shivom is powering the next era of genomics through blockchain technology – protecting identity, personalizing healthcare and transforming lives. For the first time ever, a precision medicine ecosystem will offer an open web-marketplace for other providers to add not only genomics information, but also analytics and associated apps and services to drive personalized medicine. Shivom intends to extend its services to form a global network of associated laboratories and research centres, as well as genetic counsellors and other relevant services.  For further information, please visit: http://35.231.194.138/

About Lifebit
Lifebit is building a cloud-based cognitive system that can reason about DNA data like humans do. This offers researchers/R&D professionals, and their corresponding organizations (ie. pharmas), a highly scalable, modular and reproducible system that automates the analysis processes, learns from the data and provides actionable insights. For further information, please visit: https://lifebit.ai

Recent Updates

View All

Our Alpha Public Release!

Back in August, we announced that we would be releasing a platform in order for our community to test and give us feedback on the first iteration of our Alpha product.

After onboarding a wealth of new talent and welcoming Henry Ines to the role of CEO, we felt it time to take a step back and reassess our current position. We realized that many of our competitors, both startups in the blockchain space and traditional genetics companies had spent a significant amount of time streamlining their UI/UX and USPs. It became clear to us that we needed to innovate in an area that’s often overlooked – secure storage. In perfecting such a solution, we would be able to offer our community and competitors alike greater freedom and transparency where the storage and sharing of their DNA data is concerned, having a positive knock-on effect on the direct-to-consumer genetic testing industry.

Months of development later, after several scrum meetings and all-nighters, we’re thrilled to unveil to the community the long-awaited Alpha Release!


A Sleek UI/UX Brand Overhaul

Users will also notice that we’ve greatly simplified our sign-up process, stripping it down to three easy steps:

Select whether you’re a consumer or an enterprise user, before adding general account information (name, DOB, country, etc.)

Complete health and wellness information by answering a range of questions (which, in later releases, will not only help us better assess which products we should provide our audience with, but also improve the search function for organizations seeking particular DNA datasets). Of course, the user will be able to specify whether they wish to be ‘discoverable’ in our Enterprise Search feature.

The final step in the sign-up process is adjusting user permissions – you’ll be able to set search, viewing and contact permissions that are linked to DNA data uploaded onto the platform. We’ve implemented toggle functionality to offer users a more granular experience over categories. For instance, they may choose to only make their data searchable and available to academic research teams over governmental organizations.

DNA Upload & Encryption

As aforementioned, we’ve spent countless hours fine-tuning our secure storage feature whilst ensuring newcomers and users of previous genetic testing kits are provided with a seamless experience for securely uploading their data. If you’ve used another testing service previously, all you need is your genetic information to get started – usually, this is stored in a file with a .vcf extension.

Navigate to the MYDNA page and click on ‘Upload’ to select the requisite file from your device. Once selected, it will be encrypted and subsequently stored on the Shivom platform. In successive releases, expect an even simpler process, where logins for sites like 23andMe or Ancestry can be used in order to directly import data.

Additionally, this page allows you to pre-order home testing kits. Select this option to be added to the pre-order list for the kits, which will be shipped in Q1 of 2019.

 

What’s Next?

Shivom will continue iterating on its product and fleshing out our core features – above all, our work is driven with a focus on security and accessibility. In tandem, we’ll launch numerous upgrades to campaign management for enterprise users and our Enterprise Search function (providing granular filters for organizations seeking out specific data sets, i.e. those from specific regions, associated with certain diseases or conditions, etc.).

For users that wish to share their data with researchers or institutes in the medical field (all whilst being remunerated for their participation), we’ll be rolling out the ability to anonymously provide organizations with datasets within a set timeframe, leveraging blockchain-based payments directly into an integrated wallet accessible via Shivom’s web portal.

Stay tuned for more exciting updates on our roadmap, developments and partnerships in the coming weeks. Go ahead and experiment with the Alpha, and be sure to let us know what you like, what could be improved, and what you’d like to see added in the future via the Intercom feature at the bottom right-hand side of the portal.

Until next time,

The Shivom Team

Recent Updates

View All